프리마켓
로그인 회원가입
SABS
SABS
SAB Biotherapeutics Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$3.44
-0.07 ▼ -1.99%

사비오테라퓨틱스(SABS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$263M
스몰캡
P/E
-
배당수익률
없음
52주 위치
48%
저점 +86% · 고점 -33%
애널리스트
적극 매수
B-
Fundamental health
vs. 방어주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 52%
밸류에이션
데이터 부족
재무 안정
Top 37%
Index RUTP/E -EPS (ttm) -2.47Insider Own 15.78%Shs Outstand 75.7MPerf Week -1.99%
Market Cap 0.26BForward P/E -EPS next Y 31.78%Insider Trans -Shs Float 64.4MPerf Month -11.11%
Enterprise Value 0.16BPEG -EPS next Q -0.28Inst Own 76.54%Short Float 6.8%Perf Quarter -2.27%
Income -0.03BP/S -EPS this Y -32.73%Inst Trans 30.1%Short Ratio 4.87Perf Half Y -14.85%
Sales 0.00BP/B 1.15EPS next 5Y 3.03%ROA -18.49%Short Interest 4.38MPerf YTD -8.02%
Book/sh 3P/C 2.45EPS past 3/5Y 43.07% -ROE -21.31%52W High -33.2% ($5.15)Perf Year 34.9%
Cash/sh 1.4P/FCF -Sales past 3/5Y -ROIC -11.39%52W Low 85.95% ($1.85)Perf 3Y -59.43%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 72.96%Gross Margin -Volatility(W/M) 4.63% 5.54%Perf 5Y -96.55%
Dividend TTM -EV/Sales -Sales Y/Y TTM -100%Oper. Margin -ATR (14) 0.2Perf 10Y -
Dividend Ex-Date -Quick Ratio 11.45EPS Q/Q 37.01%Profit Margin -RSI (14) 39.18Recom 1.08
Dividend Gr. 3/5Y -Current Ratio 11.45Sales Q/Q -SMA20 -7.51% ($3.72)Beta 0.54Target Price $11.33
Payout -Debt/Eq 0.03Earnings 2026/5/12SMA50 -6.37% ($3.67)Rel Volume 0.68Prev Close $3.51
Employees 86LT Debt/Eq 0.02EPS/Sales Surpr. -64.71% -SMA200 -7.08% ($3.7)Avg Volume(3M) 0.90MPrice $3.44
IPO 2021/2/9Option/Short Yes/YesTrades 2284Volume 609,485Change -1.99%
Quarterly earnings trend SEC filings · USD
23.12*
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-19M (YoY -263%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 SAB Biotherapeutics Inc (SABS) Investment Analysis

What kind of company is SAB Biotherapeutics Inc?

사비오테라퓨틱스(SABS) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

SAB Biotherapeutics (SABS) is a US-based clinical-stage biotech company developing immunotherapies using human antibodies. Its lead candidate, SAB-142, is a disease-modifying human anti-thymocyte globulin (hATG) designed to slow the progression of Type 1 diabetes, representing a next-generation therapeutic mechanism in the autoimmune disease space.

Learn more about SAB Biotherapeutics Inc →
Market Cap
$0.3B
Approx. KRW 0.4 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3850
Employees86people
IPO2021/02/09
Current Price$3.44 ≈ 4,713원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 12일 (화) · 장 시작 전 EPS -64.7%
🔔 Earnings release 2026년 3월 9일 (월) · 장 마감 후 EPS -14.1%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-21.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-18.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-11.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.03
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
11.45
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
11.45
✓ 우수
My positionTop 25%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$11.33
현재가 대비 +229.4%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+31.8%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+3.0%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-103.4%
평균 서프라이즈
2026.05.12
하회
-64.7%
2026.03.09
하회
실적 $-0.41 · 예상 $-0.17 -142.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-32.7%
부진
My positionBottom 25%
Low range Average High range
방어주 초소형주 Median 21.2% · Bottom 21%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+31.8%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 14.5% · Top 40%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+3.0%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 3.1% · Bottom 50%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+43.1%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 30.0% · Top 40%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -165%p below the market
SABS -96.5% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-164.9%p
Significantly behind the market
vs Health Care (XLV)
-121.0%p
Significantly behind the sector average
1-year basis
vs S&P 500
+18.9%p
ahead of the market
vs Health Care (XLV)
+15.2%p
ahead of the sector average
Rank among peers
5-year return Upper-Mid (50%) Based on 245 peers
1-year return Top 17% Based on 315 peers
Current position within 52-week range
Low (-86.0%p) High (-33.2%p)
Current price is 86.0% above the 52-week low and 33.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-27.9%
Annualized volatility
61.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $3.44 below the midline ($3.72). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.064 < Signal -0.030 in negative zone + Hist negative (-0.034). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 39.4 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 1.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
1.15x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 1.35x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$11.33 vs. current price +229.4%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional net buying +30.1% · Short interest moderate 6.8% · Short interest up +2.4pp over last 89d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+30.1%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 76.5%
Adequate institutional weight
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 15.8%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 7.7%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
6.8%
Moderate
Healthcare 초소형주 Median 3.9%
Past 89 days 📈 +2.4%p increase
Short interest days to cover
4.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 75.7M주
Float (tradable shares) 64.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding SABS

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
SABS SABS This Stock
$263.0M- 1.1 -21.31% - -2.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 사비오테라퓨틱스(SABS)?

사비오테라퓨틱스(SABS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SABS?

The market cap of SABS is approximately $263M, ranking 3,850 within its sector.

What is the 52-week high and low for SABS?

SABS has recorded a 52-week high of $5.15 and a low of $1.85.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.